Axbio Inc. announced that it has received $100 million in funding from Yunfeng Capital, 5Y Capital, CBC Group, SDIC Capital Co.,Ltd, AstraZeneca PLC, Investment Arm
June 06, 2022
Share
Axbio Inc. announce that it has received $100 million in its series B round of funding led by Yunfeng Capital and AstraZeneca PLC, Investment Arm, on June 7, 2022. The transaction included participation from CBC Group, SDIC Capital Co.,Ltd and retuning investor 5Y Capital.
SDIC Capital Co., Ltd, formerly SDIC Essence (Holdings) Co., Ltd, is a China-based company principally engaged in the securities business. The Company operates through five segments. The Brokerage segment manily includes brokerage business of securities and futures and the agent sales of financial products. Entrusted Asset Management segment mainly includes the pooled asset management, directional asset management and specific asset management. Proprietary Business segment mainly invests the Companyâs funds in equity securities, fixed income securities and derivatives and is involved in the market making business in the new over-the-counter (OTC) market. Investment Banking segment includes stock financing, bond financing, mergers and acquisitions and financial advisory services. Margin Trading segment includes margin trading, stock pledged repo and agreed-to-repurchase securities.
Axbio Inc. announced that it has received $100 million in funding from Yunfeng Capital, 5Y Capital, CBC Group, SDIC Capital Co.,Ltd, AstraZeneca PLC, Investment Arm
SDIC CAPITAL CO.,LTD 
